Refine
Year of publication
Document Type
- Article (109)
- Preprint (12)
- Conference Proceeding (5)
- Book (3)
Has Fulltext
- yes (129) (remove)
Is part of the Bibliography
- no (129)
Keywords
- Mammakarzinom (12)
- breast cancer (12)
- Behandlung (8)
- Metastasen (8)
- CDK4/6 (6)
- PD1/PDL1 (6)
- Prävention (6)
- Studien (6)
- prevention (6)
- treatment (6)
- metastases (5)
- Risiko (4)
- risk (4)
- trials (4)
- metastatic (3)
- Alpelisib (2)
- Atezolizumab (2)
- Biomarkers (2)
- CV9202 (2)
- Diagnostik (2)
- Früherkennung (2)
- Healthy adults (2)
- Katherine (2)
- Lokalrezidiv (2)
- NMR spectroscopy (2)
- Nachsorge (2)
- Non-small cell lung cancer (2)
- PARP (2)
- PD1/ PDL1 (2)
- PD‑L1 (2)
- PI3K (2)
- Phylogeographie (2)
- Prognosefaktoren (2)
- Prädiktivfaktoren (2)
- Richtlinie (2)
- Supportivtherapie (2)
- T‑DM1 (2)
- adjuvant therapy (2)
- adjuvante Therapie (2)
- advanced (2)
- alpelisib (2)
- atezolizumab (2)
- diagnosis (2)
- early breast cancer (2)
- follow‑up (2)
- fortgeschritten (2)
- frühes Mammakarzinom (2)
- guideline (2)
- kidney (2)
- local recurrence (2)
- neoadjuvant therapy (2)
- neoadjuvante Therapie (2)
- phylogeography (2)
- predictive factors (2)
- prognostic factors (2)
- screening (2)
- studies (2)
- supportive therapy (2)
- survival (2)
- treatment/therapy (2)
- 1,2-Dimesitoylbenzene (1)
- ADAMTS-13 (1)
- AM1 Calculations (1)
- AML (1)
- Advanced breast cancer (1)
- Alzheimer’s dementia (1)
- Amyloid-beta 42 (1)
- Animal models (1)
- Aniridia (1)
- Anti-kaon–nucleon physics (1)
- Antihormone therapy (1)
- Aphakia (1)
- Artificial iris (1)
- Automata theory (1)
- BCOR (1)
- BCORL1 (1)
- BI1361849 (1)
- Baryonic resonances (1)
- Benthos (1)
- Biodiversität (1)
- Biotin (1)
- Blocked occlusion (1)
- Body sway (1)
- CAI-1 (1)
- CRISPR/Cas (1)
- Carrier-bound fibrin sealant (1)
- Causality assessment (1)
- Clinical Trials and Observations (1)
- Clinical trial (1)
- Cohort studies (1)
- Collagen hemostat (1)
- Council for International Organizations of Medical Sciences (1)
- Crystal Structure (1)
- Crystal structure (1)
- Cyanine Distortion (1)
- Dehydrogenase Cofactors (1)
- Direct carbon (1)
- Diversity (1)
- Duganella (1)
- EP300 (1)
- ESR Spectra (1)
- EWSR1 (1)
- Effective half-life (1)
- Electron Transfer (1)
- Electron-pion identification (1)
- Electronic Structure (1)
- Entomology (1)
- Esters (1)
- Eukaryota (1)
- Expedition Brochure (1)
- Expeditionsbericht (1)
- FAPI PET (1)
- FOXO1 (1)
- Fibre/foam sandwich radiator (1)
- Freezeout (1)
- Fusarium graminearum (1)
- G-protein-coupled receptor (1)
- Gene fusion (1)
- Genome editing (1)
- Graves’ disease (1)
- HER2 c-erbB2 (1)
- HER2/neu (1)
- Heavy ion storage ring (1)
- Heavy-ion reactions (1)
- Hemostatics (1)
- Herb induced liver injury (1)
- Herbs (1)
- Heregulin (1)
- High-pressure (1)
- Hippocampal volume (1)
- Hyperconjugation (1)
- Hypofractionated radiotherapy (1)
- IOL scleral Fixation (1)
- Immunomonitoring (1)
- Infinite games with perfect information (1)
- Internal ribosome entry site (1)
- Ionisation energy loss (1)
- Isolierung (1)
- Janthinobacterium (1)
- Kaonic nuclei (1)
- Labordiagnose (1)
- Lebensgemeinschaft (1)
- Liver resection (1)
- Low energy QCD (1)
- Luciferase (1)
- MM-121 (1)
- MNDO Calculations (1)
- Meersseman test (1)
- Meloneta alpica (1)
- Metastatic (1)
- Mild cognitive impairment (1)
- Molecular Conformation (1)
- Molecular diagnostic testing (1)
- Multi-wire proportional drift chamber (1)
- Multianvil (1)
- Myeloid Neoplasia (1)
- Neural network (1)
- Neuroepithelial tumor (1)
- Ocular trauma (1)
- Orbital electron capture (1)
- Organosilicon Compounds (1)
- Orthopaedics (1)
- Oxidation States (1)
- Oxo-and Alkylamino-Substituted p-Benzoquinone Derivatives (1)
- PAGE (1)
- PCR (1)
- PLAGL1 (1)
- Partial wave analysis (1)
- Phospho-tau (1)
- Phosphorylation (1)
- Phylogenetik (1)
- Phylogenomics (1)
- Pityogenes (1)
- Population genetics (1)
- Prediction (1)
- Protein translation (1)
- RNA (1)
- RNActive (1)
- Radical Anion Sodium Salt (1)
- Radioiodine therapy (1)
- Radioiodine uptake test (1)
- Randomized controlled trial (1)
- Rare-earth borate (1)
- Re-exposure (1)
- Registries (1)
- Ruthenium Complexes (1)
- SSCP (1)
- Scolytidae (1)
- Scolytinae (1)
- Seribantumab (1)
- Single Crystal Structures (1)
- Single particle decay spectroscopy (1)
- Substituent Effects (1)
- Supratentorial (1)
- Symmetrical blocked occlusion (1)
- T-DM1 (1)
- TLR2/6 (1)
- TR (1)
- Tau (1)
- Terbium (1)
- Thyroid (1)
- Tracking (1)
- Transition radiation detector (1)
- Translation initiation (1)
- Translational research (1)
- Trigger (1)
- Two body weak decay (1)
- Upper body posture (1)
- VARGADO (1)
- Videorasterstereography (1)
- Water balance (1)
- Weight distribution (1)
- Xenon-based gas mixture (1)
- Yamane (1)
- Zellkultur (1)
- Zooplankton (1)
- acute myeloid leukemia (1)
- advanced breast cancer (1)
- algorithms (1)
- allocation (1)
- angio-immunogenic switch (1)
- antihormone therapy (1)
- available water capacity (1)
- bacterium-fungus interaction (1)
- benthic communities (1)
- biodiversity (1)
- biogenic amine (1)
- bleeding (1)
- blood flow recovery (1)
- bortezomib (1)
- cell culture (1)
- cellular signaling (1)
- chemical vapour deposition (1)
- chemotherapy (1)
- child (1)
- collateral growth (1)
- combinatorics (1)
- dE/dx (1)
- data structures (1)
- denervation (1)
- detection (1)
- docetaxel (1)
- dopamine (1)
- drought-stress (1)
- dwarf-shrub heath (1)
- femoral artery ligation (1)
- fibrosis imaging (1)
- field-effect transistor (1)
- forest (1)
- forest site classification (1)
- fourth (1)
- graft (1)
- habitat boundary (1)
- hierarchies and reducibilities (1)
- induction chemotherapy (1)
- induction regimen (1)
- insect (1)
- interleukin-6 (1)
- intracranial hemorrhage (1)
- isolation (1)
- laboratory diagnosis (1)
- lapatinib (1)
- lenalidomide (1)
- local radiotherapy (1)
- logic (1)
- loss (1)
- loss-of-function (1)
- mRNA active cancer immunotherapy (1)
- mRNA vaccine (1)
- metastasis (1)
- mitochondrial DNA (1)
- mitochondriale DNA (1)
- mtDNA (1)
- multiple myeloma (1)
- nintedanib (1)
- non-small cell lung cancer (1)
- non-small-cell lung cancer (1)
- nuclear cardiology (1)
- oligosilanes (1)
- pertuzumab (1)
- phylogenetics (1)
- platelet substitution (1)
- ppK − (1)
- proteomics (1)
- pulmonary hypertension (1)
- quorum sensing (1)
- radiation (1)
- radiation-induced nanostructures (1)
- re-transplantation (1)
- reactive systems (1)
- renal failure (1)
- repeated (1)
- respiratorische Infektion (1)
- respiratory infection (1)
- risk stratification (1)
- salivary gland (1)
- silicon nanowires (1)
- site classification system (1)
- small proteins (1)
- specification and verification (1)
- structural biology (1)
- structure–activity relationships (1)
- third (1)
- thrombotic microangiopathy (1)
- thrombotic thrombocytopenic purpura (1)
- trastuzumab (1)
- tumor microenvironment (1)
- vapor–liquid–solid mechanism (1)
- vascular surgery (1)
- verification (1)
- violacein (1)
- von Willebrand factor (1)
- zooplankton (1)
- α-Iminoketones (1)
Institute
This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L), and trastuzumab emtansine (T-DM1). The PRAEGNANT study is a real-time, real-world registry for MBC patients. All therapy lines are documented. This analysis describes the utilization of anti-HER2 therapies as well as therapy sequences. Among 1936 patients in PRAEGNANT, 451 were HER2-positive (23.3%). In the analysis set (417 patients), 53% of whom were included in PRAEGNANT in the first-line setting, 241 were treated with H, 237 with PH, 85 with L, and 125 with T-DM1 during the course of their therapies. The sequence PH → T-DM1 was administered in 51 patients. Higher Eastern Cooperative Oncology Group (ECOG) scores, negative hormone receptor status, and visceral or brain metastases were associated with more frequent use of this therapy sequence. Most patients received T-DM1 after treatment with pertuzumab. Both novel therapies (PH and T-DM1) are utilized in a high proportion of HER2-positive breast cancer patients. As most patients receive T-DM1 after PH, real-world data may help to clarify whether the efficacy of this sequence is similar to that in the approval study.
We present measurements of exclusive ensuremathπ+,0 and η production in pp reactions at 1.25GeV and 2.2GeV beam kinetic energy in hadron and dielectron channels. In the case of π+ and π0 , high-statistics invariant-mass and angular distributions are obtained within the HADES acceptance as well as acceptance-corrected distributions, which are compared to a resonance model. The sensitivity of the data to the yield and production angular distribution of Δ (1232) and higher-lying baryon resonances is shown, and an improved parameterization is proposed. The extracted cross-sections are of special interest in the case of pp → pp η , since controversial data exist at 2.0GeV; we find \ensuremathσ=0.142±0.022 mb. Using the dielectron channels, the π0 and η Dalitz decay signals are reconstructed with yields fully consistent with the hadronic channels. The electron invariant masses and acceptance-corrected helicity angle distributions are found in good agreement with model predictions.
Methodik
(2002)
Die vegetationskundliche und strukturelle Zuordnung der Lebensraumtypen erfolgt nach der vorrangig von Braun-Blanquet entwickelten Vegetationsklassifizierung, einer hierarchischen Gliederung der Vegetationstypen (Syntaxonomie), die die Ebenen der Assoziation, des Verbandes, der Ordnung und der Klasse umfasst. Hierbei ist die Assoziation die grundlegende Einheit, in der die Pflanzengesellschaften zusammengefasst werden, die sich durch gleiche charakteristische Arten(gruppen)kombinationen auszeichnen. Der Verband vereinigt ähnliche Assoziationen. Das sind bereits umfassendere, jedoch standörtlich noch recht einheitliche Vegetationseinheiten. In Ordnungen werden ähnliche Verbände zusammengefasst. Die Klasse vereinigt ähnliche Ordnungen.
The Transition Radiation Detector (TRD) was designed and built to enhance the capabilities of the ALICE detector at the Large Hadron Collider (LHC). While aimed at providing electron identification and triggering, the TRD also contributes significantly to the track reconstruction and calibration in the central barrel of ALICE. In this paper the design, construction, operation, and performance of this detector are discussed. A pion rejection factor of up to 410 is achieved at a momentum of 1 GeV/c in p-Pb collisions and the resolution at high transverse momentum improves by about 40% when including the TRD information in track reconstruction. The triggering capability is demonstrated both for jet, light nuclei, and electron selection.
The Transition Radiation Detector (TRD) was designed and built to enhance the capabilities of the ALICE detector at the Large Hadron Collider (LHC). While aimed at providing electron identification and triggering, the TRD also contributes significantly to the track reconstruction and calibration in the central barrel of ALICE. In this paper the design, construction, operation, and performance of this detector are discussed. A pion rejection factor of up to 410 is achieved at a momentum of 1 GeV/c in p-Pb collisions and the resolution at high transverse momentum improves by about 40% when including the TRD information in track reconstruction. The triggering capability is demonstrated both for jet, light nuclei, and electron selection.
The Transition Radiation Detector (TRD) was designed and built to enhance the capabilities of the ALICE detector at the Large Hadron Collider (LHC). While aimed at providing electron identification and triggering, the TRD also contributes significantly to the track reconstruction and calibration in the central barrel of ALICE. In this paper the design, construction, operation, and performance of this detector are discussed. A pion rejection factor of up to 410 is achieved at a momentum of 1 GeV/c in p–Pb collisions and the resolution at high transverse momentum improves by about 40% when including the TRD information in track reconstruction. The triggering capability is demonstrated both for jet, light nuclei, and electron selection.
The first measurement of ϕ-meson production in p-Pb collisions at a nucleon-nucleon centre-of-mass energy sNN−−−√ = 5.02 TeV has been performed with the ALICE apparatus at the LHC. The ϕ-mesons have been identified in the dimuon decay channel in the transverse momentum (pT) range 1<pT<7 GeV/c, both in the p-going (2.03<y<3.53) and the Pb-going (−4.46<y<−2.96) directions, where y stands for the rapidity in the nucleon-nucleon centre-of-mass. Differential cross sections as a function of transverse momentum and rapidity are presented. The forward-backward asymmetry for ϕ-meson production is measured for 2.96<|y|<3.53, resulting in a factor ∼0.5 with no significant pT dependence within the uncertainties. The pT dependence of the ϕ nuclear modification factor RpPb exhibits an enhancement up to a factor 1.6 at pT = 3-4 GeV/c in the Pb-going direction. The pT dependence of the ϕ-meson cross section in pp collisions at s√ = 2.76 TeV, which is used to determine a reference for the p-Pb results, is also presented here for 1<pT<5 GeV/c and 2.5<y<4.
We report on results obtained with the Event Shape Engineering technique applied to Pb-Pb collisions at sNN−−−√=2.76 TeV. By selecting events in the same centrality interval, but with very different average flow, different initial state conditions can be studied. We find the effect of the event-shape selection on the elliptic flow coefficient v2 to be almost independent of transverse momentum pT, as expected if this effect is due to fluctuations in the initial geometry of the system. Charged hadron, pion, kaon, and proton transverse momentum distributions are found to be harder in events with higher-than-average elliptic flow, indicating an interplay between radial and elliptic flow.
Transverse momentum (pT) spectra of pions, kaons, and protons up to pT=20 GeV/c have been measured in Pb-Pb collisions at sNN−−−√=2.76 TeV using the ALICE detector for six different centrality classes covering 0-80%. The proton-to-pion and the kaon-to-pion ratios both show a distinct peak at pT≈3 GeV/c in central Pb-Pb collisions that decreases towards more peripheral collisions. For pT>10 GeV/c, the nuclear modification factor is found to be the same for all three particle species in each centrality interval within systematic uncertainties of 10-20%. This suggests there is no direct interplay between the energy loss in the medium and the particle species composition in the hard core of the quenched jet. For pT<10 GeV/c, the data provide important constraints for models aimed at describing the transition from soft to hard physics.
Observation of enhanced subthreshold K+ production in central collisions between heavy nuclei
(1994)
In the very heavy collision system 197Au+197Au the K+ production process was studied as a function of impact parameter at 1 GeV/nucleon, a beam energy well below the free N-N threshold. The K+ multiplicity increases more than linearly with the number of participant nucleons and the K+/ pi + ratio rises significantly when going from peripheral to central collisions. The measured K+ double differential cross section is enhanced by a factor of 6 compared to microscopic transport calculations if secondary processes (Delta N-->K Lambda N and Delta Delta -->K Lambda N) are ignored.